Contents

Search

lumacaftor

Indications: - used in combination with ivacaftor for treatment of cystic fibrosis CFTR mutation F508del Dosage: - 200 mg Mechanism of action: - CFTR potentiator

General

pulmonary agent heterocyclic compound, 1 ring amide ether

Database Correlations

PUBCHEM cid=16678941

References

  1. FDA News Release. July 2, 2015 FDA approves new treatment for cystic fibrosis http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm453565.htm

Component-of

ivacaftor/lumacaftor (Orkambi)